Clear Street’s Sarepta Therapeutics SRPT Stock Holding History

Clear Street’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-45,000	Closed	-$4.97M	–	1145
2022 Q3	$4.97M	Buy	+45,000	New	+$4.54M	0.12%	85

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Clear Street's SRPT Position: Q2 2026 in Review

Clear Street sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 361,391 shares — an estimated $7.86M sold.

Clear Street first reported a position in SRPT in Q4 2025 and held it in 2 quarters. The position peaked at $9.32M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Clear Street reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
Clear Street sold 361,391 Sarepta Therapeutics shares in Q2 2026, an estimated $7.86M.
Clear Street first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 2 quarters.
Clear Street's Sarepta Therapeutics position peaked at $9.32M in Q4 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.